China’s national pharmaceutical group, also known as Sinopharm, consists of 1,500 Filipinos from more than 30,000 volunteers who participated in the Phase III clinical trial of the Covid-19 vaccine company, according to Chinese Ambassador to the Philippines Huang Xilian.
The envoy added that there are also volunteers in the United Arab Emirates who have been in the drug’s Phase III clinical trial since June 23.
The company has also introduced the Phase III clinic in other countries, adding Bahrain, Argentina, Peru and Morocco, involving more than 50,000 volunteers from 115 countries.
According to Huang, who was interviewed Tuesday at the Daily Tribune’s Show Straight Talk, thousands of others have been vaccinated with the Sinopharm vaccine since China introduced the emergency use of Covid-19 vaccines on July 22, “without serious adverse effects. , or an infection. “
It added that applicable tests of the Sinopharm vaccine against the main strains of the Covid-19 virus had been carried out, in addition to those of Beijing Xinfadi, as well as other regions of Russia, the United Kingdom, the United States, Austria, etc. has shown promising effects in terms of protection and effectiveness.
When asked when the vaccines would be fit for use in mass advertising, Huang, referring to Sinopharm, said that “the vaccine will probably be on the market until the end of December 2020. “
“The company has built two high-level biosecurity production facilities in Beijing and Wuhan with an annual production capacity of three hundred million doses,” he said.
Huang said an additional expansion of production capacity would allow the company to produce 800 million to one billion doses per year.
During the webinar, Huang said, the third phase of the trial began in June and would end in October this year.
“After the third phase of the trial and the vaccine have been successful, Sinopharm will participate in a publicity deal to manufacture the vaccine and it will be ready to ship until the end of the year or early next,” he said.
Huang said that since the Covid-19 outbreak, China has been actively involved in development and vaccine.
Currently, the World Health Organization has registered 34 candidate vaccines that are being clinically evaluated worldwide.
“There are now 8 candidate vaccines in the Phase III trial, which is the last phase before advertising use. Four candidate vaccines come from Chinese vaccine developers, adding 2 from Sinopharm, a subsidiary of China’s largest vaccine producer, China National Pharmaceutical Group [CNBG”], one from Sinovac Biotech and one from CanSino Biological. »
When you visit our site, you are satisfied with our privacy policy related to cookies, tracking statistics, etc.